Effects of sildenafil citrate on human hemodynamics

American Journal of Cardiology

Volumn 83, Issue 5 A, 1999, Pages 13-20

  Jackson, Graham ^a   Benjamin, Nigel ^b   Jackson, Neville ^c   Allen, Michael J ^c  

^a GUY'S AND ST THOMAS' NHS FOUNDATION TRUST   (United Kingdom)

^b ST BARTHOLOMEW S HOSPITAL   (United Kingdom)

^c PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

SILDENAFIL;

ADULT; ARTICLE; BLOOD PRESSURE; DRUG EFFECT; DRUG TOLERABILITY; FOREARM BLOOD FLOW; HEADACHE; HEART OUTPUT; HEART RATE; HEMODYNAMIC MONITORING; HUMAN; HUMAN EXPERIMENT; INTRAARTERIAL DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; LUNG ARTERY PRESSURE; MALE; NORMAL HUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; SYSTEMIC VASCULAR RESISTANCE; VEIN COMPLIANCE;

EID: 0033522152     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9149(99)00043-0     Document Type: Article

References (14)

1. Umans J.G., Levi R. Nitric oxide in the regulation of blood flow and arterial pressure. Ann Rev Physiol. 57:1995;771-790.
2. Burnett A.L. Nitric oxide in the penis physiology and pathology . J Urol. 157:1997;320-324.
3. Ballard S.A., Gingell C.J., Tang K., Turner L.A., Price M.E., Naylor A.M. Effects of sildenafil on the relaxation of human corpus cavernosum tissue in vitro and on the activities of cyclic nucleotide phosphodiesterase isozymes. J Urol. 159:1998;2164-2171.
4. Moreland R.B., Goldstein I., Traish A. Sildenafil, a novel inhibitor of phosphodiesterase type 5 in human corpus cavernosum smooth muscle cells. Life Sci. 62:1998;309-318.
5. Boolell M., Allen M.J., Ballard S.A., Gepi-Attee S., Muirhead G.J., Naylor A.M., Osterloh I.H., Gingell C. Sildenafil an orally active type 5 cyclic GMP-specific phosphodiesterase inhibitor for the treatment of penile erectile dysfunction . Int J Impot Res. 8:1996;47-52.
6. Jeremy J.Y., Ballard S.A., Naylor A.M., Miller M.A.W., Angelini G.D. Effects of sildenafil, a type-5 cGMP phosphodiesterase inhibitor, and papaverine on cyclic GMP and cyclic AMP levels in the rabbit corpus cavernosum in vitro. Br J Urol. 79:1997;958-963.
7. Waldman S.A., Murad F. Cyclic GMP synthesis and function. Pharmacol Rev. 39:1987;163-196.
8. Goldstein H., Lue T.F., Padma-Nathan H., Rosen R.C., Steers W.D., Wicker P.A. Oral sildenafil in the treatment of erectile dysfunction. N Engl J Med. 338:1998;1397-1404.
9. Padma-Nathan H., Steers W.D., Wicker P.A. Efficacy and safety of oral sildenafil in the treatment of erectile dysfunction a double-blind, placebo-controlled study of 329 patients . Int J Clin Pract. 52:1998;1-5.
10. Beavo J.A. Cyclic nucleotide phosphodiesterases functional implications of multiple isoforms . Physiol Rev. 75:1995;725-748.
11. Webb D.J., Boolell M., Muirhead G. Cardiovascular effects of phosphodiesterase type 5 inhibition with concomitant nitrate therapy. (Abstr.) Circulation. 98:(suppl 17):1998;I-637.
12. Morales A., Gingell C., Collins M., Wicker P.A., Osterloh I.H. Clinical safety of oral sildenafil citrate (VIAGRA) in the treatment of erectile dysfunction. Int J Impot Res. 10:1998;69-74.
13. Cooper J.D.H., Muirhead D.C., Taylor J.E., Baker P.R. Development of an assay for the simultaneous determination of sildenafil (Viagra) and its metabolite (UK-103,320) using automated sequential trace enrichment of dialysates and high-performance liquid chromatography. J Chromatogr. B701:1997;87-95.
14. Parker J.D., Parker J.O. Nitrate therapy for stable angina pectoris. N Engl J Med. 338:1998;520-531.